Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Raises $11M in Offering

NEW YORK (GenomeWeb News) – Response Biomedical said today that it has grossed C$12.7 million ($11.1 million) through a public offering, and it plans to use the funds for general operating costs and for capital acquisitions.

The company said it issued 73,333,333 units at a price of C$0.15 per unit, and that it concurrently issued an additional 11 million units pursuant to the exercise-in-full of an over-allotment option it granted to the underwriter.

Each unit consists of one common share and one-half of one common warrant, with each warrant entitling the shareholder to buy an additional common share at C$.25.

Response also granted 2.53 million common share warrants to the underwriter, with each broker's warrant entitling the holder to buy one common share at $C.25 within 24 months of the closing date of the offering.

Response Biomedical also said it expects the sale to move the Toronto Stock Exchange to terminate a delisting review of the company's shares.

Filed under

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.